| Filed On | Filing |
|---|---|
| 26 Oct 2026 |
Proxy statement: annual meeting on November 9, 2026
CEO pay $2.3M, up 23% |
| 20 Oct 2026 | CURRENT REPORT |
| 20 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. |
| 19 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure
Brisbane, CA, October 14, 2026 – Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, ... |
| 16 Oct 2026 | PRELIMINARY PROXY STATEMENT |
| 14 Oct 2026 | D |
| 02 Oct 2026 |
Form 4: Smith Nancy Freda, Director
Granted 25,000 Stock Option (right to buy) |
| 02 Oct 2026 |
Form 3: Smith Nancy Freda, Director
No securities owned |
| 02 Oct 2026 | PROSPECTUS |
| 01 Oct 2026 | EFFECT |
| 28 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers +1 more
THIS MASTER SERVICE AGREEMENT (this “Agreement”) is entered into as of this 22 day of September 2026 (the “Effective Date”), by and between FACTOR BIOSCIENCE INC., a corporation organized and existing under the laws of the State of Delaw... |
| 25 Sep 2026 | REGISTRATION STATEMENT |
| 17 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
THIS EXCLUSIVE COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of this 14th day of September 2026 (the “Effective Date”), by and between HEBEI SENLANG BIOTECHNOLOGY CO., LTD., a company organized and exi... |
| 16 Sep 2026 | DEFA14A |
| 16 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders; Other Events
The information disclosed in Item 8.01 of this Current Report on Form 8-K is incorporated herein by reference. |
| 15 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
This Securities Purchase Agreement (this “Agreement”) is dated as of September 11, 2026, between Tempest Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, inclu... |
| 01 Sep 2026 | 424B3 |
| 31 Aug 2026 | EFFECT |
| 27 Aug 2026 | CORRESP |
| 27 Aug 2026 | UPLOAD |
Loading...
